Your browser doesn't support javascript.
loading
Clinical and Molecular Characterization of Adult Glioblastomas in Southern Brazil.
Trevisan, Patricia; Graziadio, Carla; Rodrigues, Dayane Bohn Koshiyama; Rosa, Rafael Fabiano Machado; Soares, Fabiano Pasqualotto; Provenzi, Valentina Oliveira; de Oliveira, Ceres Andréia Vieira; Paskulin, Giorgio Adriano; Varella-Garcia, Marileila; Zen, Paulo Ricardo Gazzola.
Afiliación
  • Trevisan P; Graduate Program in Pathology.
  • Graziadio C; Clinical Genetics, Department of Internal Medicine, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
  • Rodrigues DBK; Graduate Program in Pathology.
  • Rosa RFM; Graduate Program in Pathology.
  • Soares FP; Clinical Genetics, Department of Internal Medicine, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
  • Provenzi VO; Neurosurgery Section, Hospital Beneficência Portuguesa de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
  • de Oliveira CAV; Pathology Section, Grupo Hospitalar Conceição, Porto Alegre, Rio Grande do Sul, Brazil.
  • Paskulin GA; Instituto de Educação e Pesquisa do Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brazil.
  • Varella-Garcia M; Graduate Program in Pathology.
  • Zen PRG; Division of Medical Oncology, Department of Medicine, University of Colorado, Aurora, Colorado.
J Neuropathol Exp Neurol ; 78(4): 297-304, 2019 04 01.
Article en En | MEDLINE | ID: mdl-30840759
We investigated 113 adult Brazilian patients with glioblastoma (GBM) for comparison with patients from distinct geographical areas and evaluation of suitability for novel targeted therapies. Patients were assessed for clinical features and tumor genomic characteristics such as ROS1 and NTRK1 rearrangements, KIT, PDGFRA, and KDR amplification, and RB1 deletion using multicolor fluorescence in situ hybridization. The majority of patients were male (53%), over 40 years (94%), with tumor located in single site (64%), in the right cerebral hemisphere (60%), and underwent partial resection (71%); 14% presented complications after surgery. The main clinical sign at diagnosis was focal abnormality (57%); frontal (31%); and temporal (20%) regions were most commonly affected. Median hospitalization time was 20 days, median survival was 175 days. One tumor was positive for rearrangement in NTRK1 and another in ROS1 (0.9% each). PDGFRA was amplified in 20% of cases, often co-amplified with KDR (>90%) and KIT (>60%). RB1 was deleted in 16% of patients. There was no association between these molecular abnormalities and patient survival. However, older age, complications after surgery, and right-sided tumors were independent variables associated with patient survival. This study contributes information on the molecular profile of glioblastomas in Latin America possibly supporting new target therapies.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Glioblastoma Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: America do sul / Brasil Idioma: En Revista: J Neuropathol Exp Neurol Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Glioblastoma Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: America do sul / Brasil Idioma: En Revista: J Neuropathol Exp Neurol Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido